473 related articles for article (PubMed ID: 14767530)
41. Functional properties of WT1.
Haber DA; Englert C; Maheswaran S
Med Pediatr Oncol; 1996 Nov; 27(5):453-5. PubMed ID: 8827073
[TBL] [Abstract][Full Text] [Related]
42. Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy.
Xu XF; Zhou SW; Zhang X; Ye ZQ; Zhang JH; Ma X; Zheng T; Li HZ
Asian J Androl; 2006 Jul; 8(4):455-62. PubMed ID: 16763722
[TBL] [Abstract][Full Text] [Related]
43. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction.
Hahm ER; Arlotti JA; Marynowski SW; Singh SV
Clin Cancer Res; 2008 Feb; 14(4):1248-57. PubMed ID: 18281560
[TBL] [Abstract][Full Text] [Related]
44. Coexpression of Wilms' tumor suppressor 1 (WT1) and androgen receptor (AR) in the genital tract of human male embryos and regulation of AR promoter activity by WT1.
Köhler B; Delezoide AL; Boizet-Bonhoure B; McPhaul MJ; Sultan C; Lumbroso S
J Mol Endocrinol; 2007 May; 38(5):547-54. PubMed ID: 17496156
[TBL] [Abstract][Full Text] [Related]
45. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
[TBL] [Abstract][Full Text] [Related]
46. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
[TBL] [Abstract][Full Text] [Related]
47. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
48. Phytoestrogens from Belamcanda chinensis regulate the expression of steroid receptors and related cofactors in LNCaP prostate cancer cells.
Thelen P; Peter T; Hünermund A; Kaulfuss S; Seidlová-Wuttke D; Wuttke W; Ringert RH; Seseke F
BJU Int; 2007 Jul; 100(1):199-203. PubMed ID: 17488304
[TBL] [Abstract][Full Text] [Related]
49. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
Nesslinger NJ; Shi XB; deVere White RW
Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
[TBL] [Abstract][Full Text] [Related]
50. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
51. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
52. Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24.
Lebedeva IV; Sarkar D; Su ZZ; Kitada S; Dent P; Stein CA; Reed JC; Fisher PB
Oncogene; 2003 Nov; 22(54):8758-73. PubMed ID: 14647471
[TBL] [Abstract][Full Text] [Related]
53. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
Miyake H; Nelson C; Rennie PS; Gleave ME
Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
[TBL] [Abstract][Full Text] [Related]
54. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer.
Rothermund CA; Kondrikov D; Lin MF; Vishwanatha JK
Prostate Cancer Prostatic Dis; 2002; 5(3):236-45. PubMed ID: 12496988
[TBL] [Abstract][Full Text] [Related]
55. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
56. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage.
Lin Y; Fukuchi J; Hiipakka RA; Kokontis JM; Xiang J
Cell Res; 2007 Jun; 17(6):531-6. PubMed ID: 17404601
[TBL] [Abstract][Full Text] [Related]
57. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
58. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling.
Jung C; Kim RS; Zhang HJ; Lee SJ; Jeng MH
Cancer Res; 2004 Dec; 64(24):9185-92. PubMed ID: 15604291
[TBL] [Abstract][Full Text] [Related]
59. [Inhibitory effect of WT1 gene isoform transfection on proliferation of leukemia cell line NB4].
Shen HL; Chen ZX; Wang W; Cen JN; Hu SY; Zhao Y
Ai Zheng; 2006 Feb; 25(2):163-9. PubMed ID: 16480579
[TBL] [Abstract][Full Text] [Related]
60. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
